MAZZARELLA, LUCA
MAZZARELLA, LUCA
Universita' degli Studi di MILANO
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion
2024 R. Pallavi, E. Gatti, T. Durfort, M. Stendardo, R. Ravasio, T. Leonardi, P. Falvo, B.A. Duso, S. Punzi, A. Xieraili, A. Polazzi, D. Verrelli, D. Trastulli, S. Ronzoni, S. Frascolla, G. Perticari, M. Elgendy, M. Varasi, E. Colombo, M. Giorgio, L. Lanfrancone, S. Minucci, L. Mazzarella, P.G. Pelicci
High-Fat Diet Promotes Acute Promyelocytic Leukemia through PPARδ-Enhanced Self-renewal of Preleukemic Progenitors
2024 L. Mazzarella, P. Falvo, M. Adinolfi, G. Tini, E. Gatti, R. Piccioni, E. Bonetti, E. Gavilán, D. Valli, A. Gruszka, M. Bodini, B. Gallo, S. Orecchioni, G. de Michele, E. Migliaccio, B.A. Duso, S. Roerink, M. Stratton, F. Bertolini, M. Alcalay, G.I. Dellino, P.G. Pelicci
Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer
2024 P. Di Chiaro, L. Nacci, F. Arco, S. Brandini, S. Polletti, A. Palamidessi, B. Donati, C. Soriani, F. Gualdrini, G. Frigè, L. Mazzarella, A. Ciarrocchi, A. Zerbi, P. Spaggiari, G. Scita, S. Rodighiero, I. Barozzi, G.R. Diaferia, G. Natoli
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience
2023 M. Repetto, E. Crimini, L. Boscolo Bielo, E. Guerini-Rocco, L. Ascione, A. Bonfanti, C. Zanzottera, L. Mazzarella, A. Ranghiero, C. Belli, C. Criscitiello, A. Esposito, M.C.P. Barberis, G. Curigliano
Inhibition of the lysine demethylase LSD1 modulates the balance between inflammatory and antiviral responses against coronaviruses
2023 L. Mazzarella, F. Santoro, R. Ravasio, V. Fumagalli, P.E. Massa, S. Rodighiero, E. Gavilán, M. Romanenghi, B.A. Duso, E. Bonetti, L. Manganaro, R. Pallavi, D. Trastulli, I. Pallavicini, C. Gentile, S. Monzani, T. Leonardi, S. Pasqualato, G. Buttinelli, A. Di Martino, G. Fedele, I. Schiavoni, P. Stefanelli, G. Meroni, R. de Francesco, C. Steinkuhler, G. Fossati, M. Iannacone, S. Minucci, P.G. Pelicci
High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias
2023 A. Magi, G. Mattei, A. Mingrino, C. Caprioli, C. Ronchini, G. Frigè, R. Semeraro, D. Bolognini, A. Rambaldi, A. Candoni, E. Colombo, L. Mazzarella, P.G. Pelicci
The clinical impact of continued smoking in patients with breast and other hormone-dependent cancer: A systematic literature review
2023 M. Del Riccio, V. Vettori, S. Raimondi, C. Lorini, G. Masala, M.S. Cattaruzza, L. Mazzarella, G. Bonaccorsi, M. Masiero, B. Bendinelli, G. Curigliano, G. Pravettoni, E. Pastore, S. Gandini, S. Caini
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Quantifying geographical accessibility to cancer clinical trials in different income landscapes
2022 G. Tini, D. Trapani, B.A. Duso, P. Beria, G. Curigliano, P.G. Pelicci, L. Mazzarella
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
2022 E. Crimini, M. Repetto, P. Tarantino, L. Ascione, G. Antonarelli, E.G. Rocco, M. Barberis, L. Mazzarella, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
TMBleR, a bioinformatic tool to optimize TMB estimation and predictive power
2021 L. Fancello, A. Guida, G. Frige, A.G. Michel Ceol, G. Babini, G.L. Scaglione, M. Zanfardino, T. Mazza, L. Ferrando, P.G. Pelicci, L. Mazzarella
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality
2021 P. Tarantino, L. Mazzarella, A. Marra, D. Trapani, G. Curigliano
Machine learning-based reclassification of germline variants of unknown significance: The RENOVO algorithm
2021 V. Favalli, G. Tini, E. Bonetti, G. Vozza, A. Guida, S. Gandini, P.G. Pelicci, L. Mazzarella
The Challenge of Choosing the Best Classification Method in Radiomic Analyses: Recommendations and Applications to Lung Cancer CT Images
2021 F. Corso, G. Tini, G. Lo Presti, N. Garau, S.P. De Angelis, F. Bellerba, L. Rinaldi, F. Botta, S. Rizzo, D. Origgi, C. Paganelli, M. Cremonesi, C. Rampinelli, M. Bellomi, L. Mazzarella, P.G. Pelicci, S. Gandini, S. Raimondi
Prospective validation of the Italian alliance against cancer lung panel in patients with advanced non–small-cell lung cancer
2021 V. Gregorc, L. Mazzarella, C. Lazzari, P. Graziano, P. Vigneri, C. Genova, L. Toschi, G. Ciliberto, L. Bonanno, A. Delmonte, G. Bucci, A. Rossi, G. Motta, S. Coco, A. Marinello, S. Buglioni, M.G. Cangi, C. Di Micco, A. Bandiera, S. Bonfiglio, L. Pecciarini, A. Guida, A. Ceol, G. Frige', R. De Maria, P.G. Pelicci
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
2021 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
2021 E. de Guillebon, M. Jimenez, L. Mazzarella, F. Betsou, P. Stadler, I. Peták, E. Jeannot, L. Chanas, N. Servant, G. Marret, B.A. Duso, F. Legrand, K.N. Kornerup, S.H. Bernhart, G. Balogh, R. Dóczi, P. Filotás, G. Curigliano, I. Bièche, J. Guérin, A. Dirner, C. Neuzillet, N. Girard, E. Borcoman, L. Larbi Chérif, P. Tresca, D.B. Roufai, C. Dupain, S. Scholl, F. André, X. Fernandez, T. Filleron, M. Kamal, C. Le Tourneau